,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'mbc', 'breast', 'destinybreast04', 'paradigm']
#asco22
#destinybreast04 practice-changing results for #trastuzumabderuxtecan in patients with #her2low #mbc after 1-2 prior chemotherapy lines paradigm shift for the classification and treatment of metastatic #breastcancer #shanimodi 
@EORTC Breast Cancer Group’s (BCG) mission is to develop new standards of care for #BreastCancer patients through innovation and multidisciplinary research.